Assessing Ionis Pharmaceuticals (IONS) Valuation After FDA Priority Review for Zilganersen
Ionis Pharmaceuticals (IONS) is back in focus after the FDA accepted its New Drug Application for zilganersen and granted Priority Review, a key regulatory step for its Alexander disease program.
See our latest analysis for Ionis Pharmaceuticals.
The FDA news comes after a mixed recent run for the stock. A 1-year total shareholder return of 162.24% contrasts with weaker 30-day and year-to-date share price returns, suggesting strong longer term momentum while shorter term enthusiasm has cooled.
If this kind of drug pipeline story interests you, it can be helpful to see what else is on the move in healthcare. Take a look at our screener of 37 healthcare AI stocks
With Ionis trading at US$74.79 and an intrinsic value estimate that implies roughly a 71% discount, the gap to consensus price targets raises a key question: is this cautious pricing, or is the market already accounting for potential future growth?
Most Popular Narrative: 20.3% Undervalued
At a last close of $74.79 against a narrative fair value of $93.90, Ionis is framed as undervalued, with that gap tied closely to its late stage pipeline.
The rapid revenue growth and positive launch trajectory for Tryngolza in familial chylomicronemia syndrome (FCS), along with the imminent launch of Donidalorsen for HAE and multiple late-stage pipeline assets reading out or launching by 2027, are set to drive sustained, stepwise increases in top-line revenue and operating leverage as Ionis transitions from R&D-heavy to commercial-stage. Expanding addressable patient populations, from rare diseases to larger segments like severe hypertriglyceridemia (sHTG), combined with favorable physician feedback and significant unmet need, position Ionis to capture substantial market share and revenue growth from trends tied to the rise in chronic disease and an aging population.
Curious what justifies this gap between price and fair value? The narrative leans on fast revenue expansion, a swing toward profitability, and a valuation multiple far outside typical biotech ranges.
Result: Fair Value of $93.90 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this narrative can unravel if key late stage approvals stumble, or if pricing and reimbursement pushbacks squeeze Olezarsen and broader RNA therapy margins.
Find out about the key risks to this Ionis Pharmaceuticals narrative.
Another View: What The Market Multiple Is Saying
The valuation story looks very different when you stop looking at future cash flows and focus on what investors are paying for sales today. Ionis trades on a P/S of 13.1x, compared with 11x for the US biotech industry and 4.1x for peers, while the fair ratio is 4.7x.
That kind of gap suggests plenty of optimism already baked into the price, even alongside a model that frames the shares as 71.2% below fair value. For you, the tension is simple: is this a rare mispricing, or is sentiment already running ahead of fundamentals for a loss making company?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of optimism and caution around Ionis leaves you on the fence, now is a good time to review the underlying numbers, risks, and growth drivers yourself, and then weigh up the 2 key rewards and 1 important warning sign
Looking for more investment ideas?
If Ionis has caught your attention, do not stop here. Broaden your watchlist with fresh ideas that match your style before the next move passes you by.
- Target potential upside by scanning a curated set of screener containing 25 high quality undiscovered gems that many investors may not be watching yet.
- Prioritise resilience by reviewing 67 resilient stocks with low risk scores that pair steadier risk profiles with clear, transparent fundamentals.
- Focus on financial strength by filtering for companies in the solid balance sheet and fundamentals stocks screener (39 results) that can better handle tough conditions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com